Pacific Biosciences Of California (PACB) Income towards Parent Company (2010 - 2026)
Pacific Biosciences Of California (PACB) posted quarterly Income towards Parent Company of -$8.3 million for Q1 2026, up 98.06% year-over-year from -$4.2 million in Q1 2025, and up 79.5% quarter-over-quarter from -$40.4 million in Q4 2025.
Pacific Biosciences Of California (PACB) Income towards Parent Company (2010 - 2026) Analysis & Trends
Pacific Biosciences Of California's Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$8.3 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 98.06% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$128.6 million (up 80.45% YoY), while the FY2025 annual figure was -$546.4 million, down 76.34% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$8.3 million, up from -$40.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $2.4 million in Q4 2024, with the low at -$426.1 million in Q1 2025.
- The 5-year median for Income towards Parent Company is -$71.4 million (2022), against an average of -$87.4 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company soared 102.89% in 2024, then slumped 1802.7% in 2025.
- Pacific Biosciences Of California's Income towards Parent Company stood at -$84.4 million in 2022, then gained by 2.8% to -$82.0 million in 2023, then jumped by 102.89% to $2.4 million in 2024, then plunged by 1802.7% to -$40.4 million in 2025, then jumped by 79.5% to -$8.3 million in 2026.
- Business Quant data shows PACB's Income towards Parent Company at -$8.3 million in Q1 2026, -$40.4 million in Q4 2025, and -$38.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn |
| 10 | Pacific Biosciences Of California | 396.09 Mn | 159.21 Mn | 12.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.74 Mn |
| Mar 31, 2026 | -8.28 Mn |
| Dec 31, 2025 | -40.37 Mn |
| Sep 30, 2025 | -38.00 Mn |
| Jun 30, 2025 | -41.93 Mn |
| Mar 31, 2025 | -426.08 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | -60.73 Mn |
| Jun 30, 2024 | -173.32 Mn |
| Mar 31, 2024 | -78.18 Mn |
| Dec 31, 2023 | -82.02 Mn |
| Sep 30, 2023 | -66.87 Mn |
| Jun 30, 2023 | -69.83 Mn |
| Mar 31, 2023 | -88.02 Mn |
| Dec 31, 2022 | -84.38 Mn |
| Sep 30, 2022 | -76.97 Mn |
| Jun 30, 2022 | -71.39 Mn |
| Mar 31, 2022 | -81.50 Mn |
| Dec 31, 2021 | -69.33 Mn |
| Jun 30, 2021 | -88.19 Mn |